This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Innovating into Active ETFs: Factor Funds Capital Management LLC
Froot, Kenneth A.; Cohen, Lauren H.; Waggoner, ScottCase HBS-211031-EFinanceKishore Karunakaran, President and COO of FFCM, faces a variety of challenges in launching an innovative investment management business in the rapidly evolving ETF space.Starting at €8.20
-
BlackRock Solutions
Froot, Kenneth A.; Waggoner, ScottCase HBS-211082-EFinanceThe BlackRock Solutions case examines the different functions and economics of a global asset manager's value chain, with particular emphasis on the "money management" and the "investment systems platform" businesses. Students analyze why BlackRock decided to unbundle its Aladdin investment platform and if the firm should consider expanding the platform in the future. Students also explore the resulting "dual-mission" challenges of servicing both...Starting at €8.20
-
Organization and Strategy at Millennium (A)
Wulf, Julie M.; Waggoner, ScottCase HBS-710415-ELeadership and People ManagementThis case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark Levin moved the firm downstream away from research and towards drug development and commercialization, while narrowing horizontal breadth from over a dozen therapeutic classes to ju...Starting at €8.20
-
Organization and Strategy at Millennium (B)
Wulf, Julie M.; Waggoner, ScottCase HBS-710418-EStrategyThis case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder CEO Mark Levin moved the firm downstream away from research and towards drug development and commercialization, while narrowing horizontal breadth from over a dozen therapeutic classes to just t...Starting at €5.74